ACCORD BIOPHARMA INC.
BiotechACCORD BIOPHARMA INC. is a biotechnology company focused on Immunology, Gastroenterology.
ACCORD BIOPHARMA INC.'s Key Drugs
ACCORD BIOPHARMA INC.'s key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ACCORD BIOPHARMA INC.'s Recent FDA Approvals
ACCORD BIOPHARMA INC. secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
ACCORD BIOPHARMA INC.'s Therapeutic Areas
ACCORD BIOPHARMA INC.'s approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ACCORD BIOPHARMA INC.'s Top Competitors
ACCORD BIOPHARMA INC.'s closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ACCORD BIOPHARMA INC. Pipeline Snapshot
Active clinical trials for ACCORD BIOPHARMA INC. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2024-04-25
- Latest
- 2026-06-05
- Applications
- 6